# TPExtreme (NCT02268695)

> Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02268695
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
- Conditions: Head and Neck Squamous Cell Carcinoma
- Interventions: Cisplatin; 5-Fluorouracile; Docetaxel; Cetuximab; granulocyte colony-stimulating factor (G-CSF)
- Enrollment: 541
- Primary outcome: Overall survival

## Indexed commentary on TPExtreme so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tpextreme-nct02268695